Category: Uncategorized

Thursday, August 06, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Awards. Graham Corporation was awarded two contracts for a combined value of over $43 million. These awards reflect the continued demand the Company is seeing across its defense platforms. The revenue for the contracts will be reflected in the Company’s first and second fiscal year 2027 backlog.

MK48 Mod 7 Heavyweight Torpedo. The first award is a follow-on fourth option year supporting the MK48 Mod 7 Heavyweight Torpedo program, awarded in the first quarter of fiscal 2027, which ended June 30, 2026. The Company will continue to provide alternators and regulators under this option year.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Wall Street woke up Wednesday to more of what it’s gotten all week: record highs, falling oil, and a fragile peace headline out of the Middle East. The financial press will lead with the Dow. The more useful question for anyone investing below the mega-cap tier is what cheaper crude actually does to small caps.

Start with the setup. After a searing rally that pushed the S&P 500 and Dow to record closes Tuesday, US futures steadied Wednesday morning. Oil fell for a third straight session — Brent slipped near $78 and WTI dropped under $75 — on growing hope that the Strait of Hormuz, the chokepoint for roughly a fifth of the world’s oil, could reopen. Qatar said a US–Iran proposal has been drafted, and Iran is reportedly weighing whether to let European navies clear mines from the waterway. Asia cheered it overnight, with South Korea’s KOSPI jumping 4%. Gold pushed higher, the VIX stayed calm, and Russell 2000 futures held firm.

Here’s why small-cap investors should care more than the headline suggests.

Small companies are the most exposed to the price of energy — and the most helped when it falls. They’re overwhelmingly domestic, they run thinner margins, and they lack the global hedging desks and pricing power of the mega-caps. When crude drops, the input-cost relief flows straight to the bottom line of small-cap industrials, transports, manufacturers, and consumer names. Cheaper oil is, in effect, a stealth margin boost for the exact companies that live closest to the edge on the income statement.

There’s a second-order effect that matters even more. Lower oil feeds disinflation, disinflation keeps the Fed’s rate-cut path alive, and small caps are the single most rate-sensitive corner of the market. Pair that with this week’s soft ADP jobs number and you get a macro mix that has historically favored the little guys.

Now the honest other side, because it cuts both ways. Energy is a meaningful slice of the Russell 2000, and cheaper crude squeezes small-cap exploration and production names hard. If your small-cap exposure leans toward oil and gas, this is a headwind, not a tailwind. The net effect depends entirely on what you own.

Step back, though, and the direction of travel is the story. The rally is finally broadening beyond the handful of AI mega-caps that carried it for two years — the Russell is joining the record run, not watching from the sidelines. A de-risking geopolitical backdrop, falling oil, and an easing Fed is the kind of trifecta that tends to reward the laggards. For two years, small caps have been the laggard.

One caveat to keep front and center: this peace is fragile, and a single headline could send oil right back up. Don’t build a thesis on a diplomatic maybe. But watch the setup. While everyone fixates on the Dow printing another record, the more interesting move may be one rung down the market-cap ladder — where the companies most helped by cheap oil and cheap money have been overlooked the longest.

Amazon shares jumped 10% in premarket trading Friday after the company topped second quarter expectations, driven by an acceleration in Amazon Web Services that one analyst covering the stock described as a genuine home run for the company. The results stood in sharp contrast to the mixed reception several other mega cap earnings reports have received this season.

AWS generated $42.2 billion in second quarter revenue, up 36.7% year over year, with strength across both its core cloud business and its expanding AI services. Amazon disclosed that its AI and custom chip businesses have each individually surpassed a $25 billion annualized revenue run rate, a figure that underscores just how quickly the AI infrastructure side of the business has scaled. The company’s custom chip business is now growing at a triple-digit year-over-year rate.

A Record Quarter of Growth

CEO Andy Jassy told investors on the earnings call that AWS added over $4.6 billion in revenue quarter over quarter, roughly 80% more than the company’s largest previous quarterly increase. The segment’s backlog now stands at $496 billion, growing at a triple-digit rate year over year. Jassy noted that customers continue choosing AWS for the breadth of its capabilities, particularly the ability to run AI inference near existing applications and data, a capability AWS offers more extensively than its competitors.

AWS is now running at approximately a $170 billion annual revenue run rate, more than four times larger than it was in 2019, illustrating the scale of growth the cloud division has achieved over the past several years.

The Capex Number That Matters

Heading into the report, Wall Street had been closely watching two things: AWS growth and capital expenditures tied to AI infrastructure. Amazon delivered on both fronts, but not in the direction some investors might have expected given the market’s recent skepticism toward AI spending. The company raised its full-year capital expenditure guidance to approximately $220 billion, up from its prior guidance of roughly $200 billion.

In a market environment where companies like Oracle and Tesla have seen their stocks punished for similarly aggressive AI-related spending increases, Amazon’s reception was notably different. Wall Street appeared willing to look past the higher spending given AWS’s accelerating growth and expanding operating margins, a combination that suggests the capital is translating into measurable revenue rather than simply funding future capacity that has yet to prove out. Jassy indicated that demand for AI and cloud computing continues to outstrip available server capacity, with planned 2027 expansion already largely booked into 2028.

What It Means for Smaller Companies in the AI Supply Chain

For investors tracking the broader technology and infrastructure ecosystem, Amazon’s report offers a useful counterpoint to the AI spending anxiety that has weighed on chip and infrastructure names throughout the summer. When a hyperscaler raises capital expenditure guidance and the market responds positively rather than punitively, it signals renewed confidence that AI infrastructure demand remains durable, at least when that spending is paired with visible, accelerating revenue growth like AWS delivered this quarter.

That distinction matters considerably for smaller companies supplying components, power infrastructure, cooling systems, and specialized hardware into the broader AI buildout. A $220 billion capital expenditure plan does not get executed through Amazon’s own engineering teams alone. It flows through an extensive supplier base, and this quarter’s results suggest that demand signal remains firmly intact even as some large cap names in the space have faced renewed investor scrutiny in recent weeks.

Tesla reported second quarter results Wednesday that missed Wall Street’s profit expectations by a wide margin, and the stock fell 14% the following session as investors weighed the earnings shortfall against the company’s confirmed plan to spend $25 billion on capital expenditures for the full year.

Adjusted earnings per share came in at $0.33, well below the approximately $0.50 analysts had expected, a miss of roughly 34%. Operating margin collapsed to 1.4% from 4.1% a year earlier, and operating income fell 57% to just $398 million. Adjusted EBITDA landed at $3.2 billion versus the $4 billion expected. On the profitability side of the ledger, this was a clear and significant miss.

Revenue told a different story. Tesla reported $28.24 billion, up 26% year over year and above the $26.32 billion Bloomberg consensus estimate. Vehicle deliveries came in at 480,126 units, up 25% year over year and well ahead of the 406,000 consensus. For the first time in company history, Tesla crossed $100 billion in trailing twelve month revenue. The top line beat. The bottom line did not, and it was the bottom line that drove the stock’s decline.

Where the Profit Miss Came From

Part of the shortfall traces back to regulatory credit income. For the first time in many quarters, those credits, which had historically contributed $700 million to $900 million per quarter to Tesla’s bottom line, came in far below that level, removing a cushion that had quietly supported margins for years.

The larger driver is capital spending. Capital expenditures surged 142% year over year to $5.79 billion for the quarter, pushing free cash flow negative at $1.09 billion. Management confirmed on the earnings call that full-year capex will total approximately $25 billion, directed almost entirely at scaling Cybercab production, building out Optimus manufacturing lines, and expanding the company’s Cortex AI compute infrastructure in Texas. CFO Vaibhav Taneja told investors that operating expenditures will continue growing through 2026 and beyond, and that commodity price increases and interest rate changes will keep adding to costs.

The Bet Behind the Spending

Every dollar of that $25 billion is aimed at a future well beyond electric vehicles. Cybercab began production and public-road testing during the quarter at Gigafactory Texas. Robotaxi service is now live in seven US metro areas. First-generation Optimus assembly lines are being installed at the Fremont factory, on space freed up after Tesla decommissioned its Model S and X production lines, with initial production targeted for later this year. Tesla Semi and Megapack 3 remain on schedule to begin production in 2026 as well.

CEO Elon Musk described this as Tesla’s largest and most exciting period of investment, acknowledging that scaling would be non-linear and reiterating a long-term value creation focus over near-term margin optimization.

What It Means for Investors Tracking the Broader Market

Tesla’s quarter fits a pattern that has now repeated across multiple high-profile earnings reports this season. TSMC beat estimates and fell. Netflix missed guidance by roughly 1% and lost $100 billion in value. Tesla beat revenue significantly, missed profit estimates badly, and confirmed a massive year of spending ahead, and the stock dropped 14% because the market is scrutinizing margin quality and cash generation with a level of skepticism it did not apply a year ago.

For companies at every market capitalization, the message from this earnings season is consistent. Strong top-line growth alone is no longer sufficient to satisfy investors who are increasingly focused on whether that growth translates into cash flow and margin durability. Companies funding aggressive expansion through negative free cash flow, regardless of how compelling the long-term vision, are being held to a higher standard of proof than they were earlier in this market cycle.

Research News and Market Data on NNVC

Wednesday, 22 July 2026 08:30 AM

SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus in the Democratic Republic of Congo (DRC).

NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together a team with a renowned Principal Investigator and other renowned experts and with support from a well known University in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebolaviruses in DRC. The Principal Investigator has sent in the application for the clinical trial.

Om Sai is also the CRO leading the Company’s Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox in DRC.

“We believe NanoViricides is well positioned to provide an Oral Ebola treatment to save lives with our NV-387 Oral Gummies drug product that is already in place in DRC,” said Anil R. Diwan, PhD, President of the Company, adding, “This unique and revolutionary oral broad-spectrum antiviral drug deserves to be tested in a clinical trial more than any antibodies or other infusion drugs.” He further commented, “Viruses readily escape antibodies after exposure to them as we know from COVID-19. Infusions are not scalable to combat an outbreak of the size that is seen in DRC.”

NV-387 is the only orally active agent under consideration for clinical trial as a treatment of Ebola to the best of our knowledge. In an epidemic scenario in resource limited settings such as in DRC, oral drug is a highly advantageous feature.

Other treatments require infusions. Infusions are difficult to implement and also are not scalable in a large outbreak scenario if this Ebola virus outbreak continues to grow, as has been widely expected.

A clinical trial of Remdesivir infusion, an antibody cocktail MBP134 infusion, and MBP134 infusion plus Remdesivir infusion, has started as per WHO with first patient having received infusion of the antibody cocktail on July 2, 2026 ¹. Monoclonal antibodies are highly specific to a particular strain of the virus and usually are not very effective against variants of the same virus that arise in the field, nor are they effective against unrelated strains of the same virus.

The Company notes that NV-387 was previously found to be superior to Remdesivir in a lethal animal model of a viral disease. The Company believes this superiority of NV-387 is reasonably expected to extend to the current novel Bundibugyo ebolavirus strain.

Sufficient quantity of NV-387 Oral Gummies Drug Product for starting the clinical trial against Ebola is already available in DRC. This drug product was shipped to DRC for the ensuing Phase II clinical trial of NV-387 for the Treatment of Mpox and also to support a Phase II clinical trial for the Treatment of Ebola if approved by the regulatory agency.

The current 17th Ebola outbreak in DRC has already claimed over 930 lives, with close to 2,400 confirmed cases, in just two months since it was declared on May 15th, becoming the fastest growing Ebola outbreak to date, as per the WHO ². This Ebola outbreak continues to increase in spread and is now present in five provinces in DRC. More concerning is the fact that over 80% of new cases are outside of known contact lists, leading to the projection that the extent of the outbreak is at least two times or more larger than the reported confirmed cases ³.

There is thus a tremendous urgency to validate a drug that works against this ebolavirus in clinical trials for minimizing further spread by treating patients and for saving lives.

There is no approved Treatment or Vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DR Congo. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source ⁴, such as fruit bats.

“We believe NV-387 could be revolutionary in this fight against Ebola, if it is found to be effective,” said Anil R. Diwan, PhD, adding, “It is an oral drug, in contrast to others that are infusions. Thus evaluating if NV-387 treatment works is of paramount importance to combat this and future Ebola and Marburg outbreaks.”

NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same host-side feature mimicked by NV-387. It is highly unlikely that viruses can escape NV-387, because this drug mimics the features on host cells that the viruses continue to require even as they mutate or evolve in the field.

Additionally, NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.

This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.

While there is currently minimal risk of Ebola in the USA, the CDC’s mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths within just three months, rivaling the largest outbreak to date in 2014-2016 ⁵. Unfortunately, the outbreak appears to be on track to realize these dire predictions.

The outbreak which was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk ⁶.

NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate proteoglycan that over 90-95% of human pathogenic viruses require for infecting cells. No matter how much the virus changes in the field, it continues to use HSPG, and therefore it cannot escape the drug NV-387. In contrast, Remdesivir is a small molecule inhibitor of the viral RDRP enzyme needed for making copies of the viral genome, and the virus can possibly escape by small number of mutations.

All Ebola viruses utilize HSPG as the attachment receptor, followed by entry into the cell inside endosomes. The virus substantially dismantles in the endosome and hitches a cognate receptor called NPC1 to enter the cytoplasm where the next steps in its replication begin.

Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.

NV-387 is available as an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.

If NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses and possibly all filoviruses; that would be a game changer for pandemic preparedness.

All previous anti-Ebola efforts have been focused on vaccines and antibodies⁷. This has led to approval of therapies that are specific to the Ebolavirus Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.

The US Government is active in ensuring that suspected or confirmed ebolavirus cases do not enter the general population in the USA. To this end, travel from DRC has been restricted, with pre-travel quarantine requirements imposed, and suspect travelers are directed to screening at specific airports and may be further quarantined.

The case fatality rate of ebolaviruses has generally been around 50% in recent outbreaks, with improvements in care, including hydration therapy, corticosteroids, and other usual symptomatic treatments. Ebola viruses spread via bodily fluid secretions including fomites/sputum, as well as semen/genital secretions. Ebola virus can remain in survivors even as many as 965 days after the disease without symptoms, and can transmit through bodily secretions, suggesting possible latency. Many recent outbreaks have been ignited as a result of such reawakened-transmitted virus from a survivor. Sexual transmission was documented even as late as 482 days after disease. This persistence and possible latency of ebolavirus in immune-privileged organs (e.g. brain, eyes, gonads, where antibodies are not operative) makes it a uniquely serious threat for global transmission and sustained outbreaks.

An irony is that because of the high case fatality rate (CFR) approaching 50%, the spread of ebolavirus remains rather limited. If a variant emerges with a reduced CFR, say in the range of 5-15%, the potential threat of global pandemic from such an outbreak would increase substantially.

So far, BDBV has demonstrated variable CFR ranging from under 15% (in Uganda, 2026), to almost 40% (in DRC, based on current confirmed cases and fatalities numbers, as of July 18, 2026). Therefore, BDBV is of great concern as a potential pandemic disease. However, it is believed that ebolaviruses do not transmit via respiratory droplets or aerosols, and require extensive contact with bodily fluids of an infected person. In addition, within DRC and internationally, certain protective quarantine measures for travel from the outbreak areas have been implemented. Therefore, currently there is no apparent threat of a global pandemic.

With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.

“Only safe and effective broad-spectrum antiviral drugs that can effectively combat most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses,” commented Dr. Diwan, adding, “NV-387 is the only drug with such potential that is in clinical development today, to the best of our knowledge.”

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide^™ class of drug candidates and the nanoviricide^™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]

Public Relations Contact:
[email protected]

Source: NanoViricides, Inc.

1 https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/

2 https://www.aljazeera.com/news/2026/7/20/ebola-death-toll-in-drc-surges-to-at-least-930-as-outbreak-gathers-pace

https://www.aljazeera.com/news/2026/7/16/ebola-spreading-more-quickly-in-drc-while-uganda-is-close-to-being-virus-free

3 https://www.msn.com/en-us/health/other/congos-ebola-outbreak-spreads-to-two-more-provinces/ar-AA27NkjT

4 b https://virological.org/t/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/1032

5 https://www.cdc.gov/media/releases/2026/update-on-ebola-outbreak-in-the-democratic-republic-of-the-congo-and-uganda-6-5-2026.html

6 https://www.forbes.com/sites/maryroeloffs/2026/05/25/african-health-officials-on-ebola-this-is-too-much-live-updates/

7 Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.

SOURCE: NanoViricides

The bond market just erased weeks of progress in a single trading session. The 10-year Treasury yield climbed to 4.64% on Tuesday, its highest level since late May, while yields across the curve rose two to four basis points as a fresh surge in crude oil prices reignited concerns that the Federal Reserve may need to raise interest rates rather than hold them steady. The move wiped out the rally that followed this month’s softer-than-expected inflation report, and it arrives just one week before the Fed’s next policy meeting.

The timing could not be more consequential. Interest rate futures now show traders pricing in roughly a 20% probability of a rate hike at next week’s FOMC meeting, up from levels near zero just days ago. Fed Chair Kevin Warsh has repeatedly emphasized that inflation remains a central concern for the committee, a position echoed by other officials in recent weeks. Policymakers are now in their customary quiet period ahead of the meeting, meaning the bond market is left to interpret incoming data without any fresh guidance from the Fed itself.

What’s Driving the Reversal

The catalyst is energy prices. Brent crude climbed to $91 a barrel Tuesday as the US and Iran exchanged strikes for a tenth consecutive day, with mediators simultaneously working to revive a fragile truce between the two countries. The renewed military escalation has pushed oil prices back toward levels that stoke inflation concerns just as markets had begun pricing in relief following the ceasefire framework from earlier this summer.

Rates strategists have pointed to a technical dimension compounding the move. The 10-year yield broke back above the closely watched 4.60% level, and the two-year yield pushed through 4.20%, both thresholds that traders monitor closely for momentum signals. That technical breakout, combined with typically thinner summer trading conditions, appears to have amplified a move that was already underway on the back of rising energy prices.

Economic data released Tuesday added further support to the case for higher yields. The Philadelphia Fed’s services sector survey showed activity expanding for the first time since October 2024, reinforcing the picture of a resilient domestic economy that gives the Fed less reason to ease and potentially more reason to consider tightening if inflation pressures continue building.

Why This Matters for Small Caps

For companies in the sub-$2 billion market cap space, this reversal is a direct reminder of how quickly the rate environment can shift against smaller, more leveraged businesses. Small and microcap companies carry disproportionately more variable-rate debt than large cap peers, which means every basis point move in Treasury yields translates into real borrowing cost changes for the companies your audience tracks most closely.

The renewed Iran escalation also revives the two-sided energy trade that has defined 2026. Consumer-facing small caps in transportation, logistics, and retail face renewed margin pressure if oil continues climbing toward $95 or higher, while domestic energy producers benefit directly from sustained prices above $90. That dynamic has whipsawed throughout the year as the conflict has cycled through ceasefires, escalations, and renewed negotiations, and Tuesday’s move suggests the pattern is far from finished.

With the Fed entering its quiet period and next week’s meeting now carrying a nontrivial probability of a hike, the coming days will be defined by how oil prices and geopolitical developments evolve, rather than by any new signal from policymakers themselves. The bond market has already cast its vote. The Fed’s response comes next Wednesday.